Researcher Profile

Dr. Sarah Johnson

PhD – Associate Professor

College of Pharmacy, Department of Pharmacology and Toxicology


s.johnson@example.edu.iq



Orcid



Scopus



Google Scholar



LinkedIn




Summary

Dr. Sarah Johnson is an Associate Professor in the Department of Pharmacology and Toxicology with over 12 years of experience in academic research and teaching. Her research focuses on neuropharmacology, specifically investigating novel therapeutic approaches for neurodegenerative disorders including Alzheimer’s and Parkinson’s disease.

Dr. Johnson completed her postdoctoral fellowship at Stanford University where she developed innovative drug delivery systems targeting the blood-brain barrier. Her current research involves preclinical studies of phytochemical compounds with neuroprotective properties, and she has published over 45 peer-reviewed articles in high-impact journals.

In addition to her research, Dr. Johnson is passionate about mentoring graduate students and has served as principal advisor for 8 PhD candidates. She teaches advanced courses in neuropharmacology and experimental therapeutics, and has developed a popular elective on the ethics of pharmacological research.

Qualifications

  • PhD in Pharmacology (2010), University of Cambridge

  • MSc in Toxicology (2006), Imperial College London

  • BSc in Pharmaceutical Sciences (2004), University of Toronto

  • Postdoctoral Research Fellowship (2010-2013), Stanford University School of Medicine

  • Visiting Scholar (2015), Karolinska Institutet

Responsibility

  • Director, Neuropharmacology Research Laboratory

  • Chair, Institutional Animal Care and Use Committee (IACUC)

  • Member, Faculty Promotion and Tenure Committee

  • Coordinator, Graduate Program in Pharmacology

  • Principal Investigator, NIH-funded research project on neuroprotective agents

Awards and Memberships

  • Distinguished Researcher Award (2021), International Society for Neurochemistry

  • Young Investigator Award (2018), American Society for Pharmacology and Experimental Therapeutics

  • Patent: “Novel Drug Delivery System for Neurodegenerative Disorders” (2020)

  • Member, Society for Neuroscience

  • Fellow, British Pharmacological Society

  • Editorial Board Member, Journal of Neuropharmacology